The Global Cell Line Development market accounted for US$ 5,279 Mn in 2020 and is expected to reach US$ 11,489 Mn by 2028 with a considerable CAGR of 10.5%during the predicted years 2021 to 2028.
Cell line development is a process of co-opting cellular machinery to produce therapeutic biological agents and other implicated proteins. Moreover, the development of stable and high-production cell lines is extremely crucial for the production of biotherapeutic products such as bispecific monoclonal antibodies, monoclonal antibodies, fusion proteins, and vaccines. For the development of cell lines, different expression systems can be used: bacterial, yeast, plant, and mammalian. The cost of drug discovery and development is extremely high. However, to reduce development costs, researchers are under increasing pressure to quickly and efficiently complete the early stages of biotherapeutic exploration and selection of biotherapeutic candidates. Additionally, these cell lines can also be used to conduct drug development research, screening, and large-scale production of compounds.
Drivers
- Growing incidences of cancer all over the globe
- Robust demand from regenerative medicines
- Development in the biotechnology industry
Restraints
- Concerns associated withthe stem-cell research
- The risk of cell line contamination
Opportunities
- Consistent research in drug development activities
- Global growth and advancements in the biotechnology industry
Report Coverage
| Market | Cell Line Development Market |
| Market Size 2021 | US$ 5,279 Mn |
| Market Forecast 2028 | US$ 11,489 Mn |
| CAGR | 10.5% During 2021 - 2028 |
| Analysis Period | 2018 - 2030 |
| Base Year | 2021 |
| Forecast Data | 2021 - 2028 |
| Segments Covered | By Product, By Source, By Type of Cell Line,By Application And By Geography |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled | Sigma-Aldrich Corp., Lonza group AG, Corning Inc., Eurofins, GE Healthcare, GenScript Biotech Corporation, Syngene International Limited, Novartis, Samsung Biologics, Horizon Discovery, Thermo Fisher Scientific Inc., and Wuxi AppTec. |
| Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
| Customization Scope |
10 hrs of free customization and expert consultation |
Global Cell Line Development Market Trends
One of the key factors fueling the cell line development market growth is the increased prevalence of cancer in developing and under-developing economies. The increase in the adoption of regenerative medicines, rising cancer prevalence globally, and soaring R&D investments by biotechnology and pharmaceutical companies are driving the cell line development market growth. Furthermore, the consistent investigation into drug discovery practices is expected to drive market growth over the forecast period. The complexity of developing stable cell lines, as well as the increased contamination due to the intense purification methods, may, however, limit the market's growth rate. In addition, the absence of regulatory standards and specific technical specifications for obtaining authorization poses a threat to the market under consideration.
Market Segmentation
Market by Product Type
- Reagents & Media
- Equipment
-
- Incubator
- Centrifuge
- Bioreactor
- Storage equipment
- Microscope
- Electroporators
- FACS
- Others
- Accessories & Consumables
Based on the product type, the reagents and media segment occupied the maximum market share in 2020. Cell culture reagents are necessary for the success of biologically relevant cell models in bioproduction and biomedical research. Media, supplements,andsera,are essential to culture reagents that promote proliferation, cell survival, and biological function. Moreover, the quality of these reagents has a direct impact on biotherapeutic production and experimental results. Besides that, selecting an optimized media for primary cells is essential for successful tissue culture assays and applications.
Market by Source
- Mammalian
- Non-Mammalian
-
- Insects
- Amphibians
Based on the source, the mammalian segment held the dominant market share in 2020. Mammalian cell culture is essential for the development of protein therapeutics and viral vaccines. The demand for high-productivity production cell lines has increased as the number of innovator biologic and biosimilars products have grown, as has the demand for the mammalian segment. Viral infection and genetic engineering can also be used to programme mammalian cells to make vaccines and therapeutic proteins. Moreover, most pharmaceutical and biotechnology companies' mammalian cell line advancement technologies are currently based on either methotrexate amplification innovation or the glutamine synthetase system.
Market by Type of Cell Line
- Recombinant
- Hybridomas
- Continuous Cell Line
- Primary Cell Line
Based on the cell line, the recombinant segment is expected to grow at the fastest CAGR during the forecast period. The rapid growth of therapeutic recombinant proteins can be attributed in large part to technological advancements in vector interpretation, cell line culture engineering, and clone screening. Recombinant proteins can be developed using a variety of expression systems, including insect, yeast, microbial, mammalian cells, and transgenic cell systems. The primary goal of recombinant protein development is to create a monoclonal cell line, which is steady and continuously expresses the specified recombinant protein in high quantity and desired quality via a productive and cost-effective production process. However, due to the similarity of their metabolic and protein processing pathways to those of human cells, mammalian cell lines are the most commonly used production systems for recombinant proteins.
Market by Application
- Drug Discovery
- Toxicity Testing
- Bioproduction
- Tissue Engineering
- Research
In terms of application, the drug discovery segment is expected to account for a significant share of the market in the coming years. Stable cell lines are widely used in a wide range of critical applications, including biologics manufacturing, drug screening, tissue engineering, and functional genomics research. Recent technological advancements by cell line development experts have aided in the testing of various drug candidates during the early development phase, saving money and time. However, the collaboration between cell line development and drug development organizations has aided the growth of the cell-line development market.
Cell Line Development Market Regional Overview
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Brazil
- Mexico
- Rest of Latin America
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Middle East & Africa
- South Africa
- GCC
- Rest of Middle East & Africa
North America is likely to dominate the global cell line development market due to its well-established advanced healthcare infrastructure and services along with increasing government initiatives. Additionally, the market in the region is expected to benefit from the implementation of innovative technologies. The United States continues to dominate the North American region with a majority stake, thanks to government support to accelerate research in the biopharmaceutical and biotechnology sectors, which has increased the demand for cell line development. Moreover, the presence of key market players, combined with the positive initiatives undertaken by the governments of this region, supports the development of cell line development activities.
Competitive Landscape
Leading players profiled in global cell line developmentindustryreport are Sigma-Aldrich Corp., Lonza group AG, Corning Inc., Eurofins, GE Healthcare, GenScript Biotech Corporation, Syngene International Limited, Novartis, Samsung Biologics, Horizon Discovery, Thermo Fisher Scientific Inc., and Wuxi AppTec.